Should we rethink methadone initiation and titration in the fentanyl era?

Methadone remains one of the most effective medications for the treatment of opioid use disorder (OUD); however, patients receiving methadone today are often very different from the patients for whom traditional induction protocols were initially developed, before the introduction of illicit fentanyl in the drug supply.¹ The current landscape surrounding our overdose crisis has shifted dramatically from nonmedical utilization of prescription opioids and heroin to the use of illicitly manufactured fentanyl and other high-potency synthetic opioids.

The proliferation of high-potency synthetic opioids in the drug supply has made it difficult to continue using current methadone initiation and titration protocols to stabilize OUD patients. Even though fentanyl has a short half-life, repeated illicit use produces pharmacokinetic and pharmacodynamic effects that differ from heroin and prescription opioids.² Illicit fentanyl has fundamentally altered the way we utilize opioid agonist treatment, including high lipophilicity, tissue sequestration, prolonged elimination, and persistent receptor occupancy.

Huhn et al provided evidence of this when they discussed the protracted renal clearance in these patients. One participant remained positive for fentanyl up to 19 days, and for norfentanyl up to 26 days.² The question we need to explore is how we properly adapt our methadone initiation and titration protocols to match what we are seeing in the drug supply and our patients.

Current Regulations Support Higher Initiation Dosing

In February 2024, the Substance Abuse and Mental Health Services Administration (SAMHSA) revised 42 CFR Part 8 of the Code of Federal Regulations (CFR), the federal guidelines governing opioid treatment programs (OTPs). This change increased the allowed total first-day methadone dose in an OTP from 30 mg to 50 mg.³ The ability to prescribe methadone doses that are pharmacologically adequate to address acquired tolerance from the utilization of illicit fentanyl would be beneficial for patients using high-potency synthetic opioids. Even though this revision in 42 CFR Part 8 applies to outpatient opioid treatment programs, it’s vital that we adapt our inpatient methadone initiation and titration protocols as well.

Noska et al discussed the importance of understanding the regulations behind the use of methadone for an inpatient.⁴ According to Title 21 of the CFR section 1306.07 C:

“This section is not intended to impose any limitations on a physician or authorized hospital staff to administer or dispense narcotic drugs in a hospital to maintain or detoxify a person as an incidental adjunct to medical or surgical treatment of conditions other than addiction, or to administer or dispense narcotic drugs to persons with intractable pain in which no relief of cure is possible, or none has been found after reasonable efforts.”

As the authors go on to explain, according to this regulation: “Methadone can be used to treat both acute withdrawal symptoms to facilitate acute inpatient care and additionally to establish opioid replacement therapy.”

The Benefits of Available Rapid Titration

Another adaptation of our methadone protocols has been the introduction of rapid titration in both the inpatient and outpatient setting. This has helped patients reach their therapeutic dose more quickly. Simon et al discussed some core reasons that patients with substance use disorders leave the hospital prematurely (and against medical advice); these included undertreated withdrawal, uncontrolled acute and chronic pain, and stigma.⁵ Rapid-dose methadone titration is one way to avoid a patient leaving the hospital prematurely by making sure they are adequately achieving therapeutic concentrations of the medication.

Racha et al conducted a retrospective, observational cohort study that looked at patients who were rapidly initiated on methadone with 30 mg as the initial dose and 10 mg increases daily until reaching 60 mg.⁶ This study showed no major adverse events and no instance of QTc prolongation. Steiger et al also conducted a rapid dose titration protocol at an outpatient OTP. They started with methadone 40 mg on day 1, 60 mg on day 2, and 80 mg on day 3, but the average dose by day 7 was 89 mg.⁷

An Open Door to Personalized Care

The 2024 revisions to 42 CFR Part 8 provide clinicians with greater flexibility to individualize methadone initiation at a time when opioid tolerance and treatment needs have changed dramatically. In the fentanyl era, the risks of methadone accumulation and respiratory depression must be balanced against the risks of prolonged withdrawal, ongoing fentanyl exposure, and treatment disengagement. For appropriately selected patients, particularly those with high opioid tolerance, more responsive titration may help achieve therapeutic dosing sooner. Whether in the OTP or inpatient setting, the goal should not simply be a higher or faster dose, but safe, individualized, and timely treatment that adequately controls withdrawal and cravings while minimizing toxicity.